Crossmark

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Crossref DOI link: https://doi.org/10.1186/s12885-021-08942-x

Published Online: 2021-11-13

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Yurong

Zheng, Ruipan

Hu, Peizhu

Zhang, Ziheng

Shen, Shujing

Li, Xingya https://orcid.org/0000-0002-8265-7318
Funding

Funding for this research was provided by:

youth innovation fund of the first affliated hospital of zhengzhou university (2019-70885; 2019-70967)
License Information

Text and Data Mining valid from 2021-11-13

Version of Record valid from 2021-11-13
More Information

Article History

Received: 8 July 2021

Accepted: 27 October 2021

First Online: 13 November 2021

Declarations

:

: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the ethics committee of First Affiliated Hospital of Zhengzhou University and individual consent for this retrospective analysis was waived.

: The consent for publication in this retrospective study was not applicable.

: The authors have no conflicts of interest to declare.

Document is current

Any future updates will be listed below